Process Validation Guidance Requirements (FDA and EU Annex 15: Qualifications and Validation)
Barry A. Friedman, Ph.D, Consultant in Biotechnology, Regulatory Compliance and Aseptic Processing Arena
Coming soon.. Please contact customer care for new schedule
The Process Validation Guidelines (January 2011) and the EU Annex 15: Qualification and Validation (October 2015) outline the general principles and approaches the two regulatory bodies consider appropriate elements of process validation for the manufacture of human and animal drugs and biological products, including Active Pharmaceutical Ingredients (APIs). These guidances align Process Validation activities with a product lifecycle concept and with existing FDA and EU guidances, including the FDA/International Conference on Harmonization (ICH), Guidance for Industry, Q8 (R2) Pharmaceutical Development, Q9 Quality Risk Management, and Q10 Pharmaceutical Quality System. The lifecycle concept, new to these Guidances, link product and process development, qualification of the commercial manufacturing process, and maintenance of the process in a state of control during routine commercial production. These guidances also support process improvement and innovation through sound science and risk management. The new Process Validation Guideline/Practice incorporate elements of Process Validation as early as the Research and Development phase, and continues onward through Technology Transfer, into the Phase 1 IND Clinical Trial manufacturing phase, and ultimately into Phase 2 and 3, and then commercial manufacturing.
Each facility, whether producing small or large molecules requires both an overall Site Validation Plan as well as specific validation plans to manage the multiplicity of validations required to confirm the successful manufacture of each of its products.
This two day, interactive Seminar which provides a conduit to enhance your understanding of the Continued Process Verification, will be reviewed in detail: where does it begin; what is included; and, when does it end.
Seminar Fee Includes:
$100 Gift Cert for next seminar
Common questions asked by the users of Process Validation include;
- How does one integrate these two different concepts (Phase 1, 2, and 3 vs. Stages 1, 2, and 3) and where do they merge?
- Do they exist independently of each other or do they complement each other to enhance, build and provide a product that neither alone could. Questions that may arise include where are cGMPs initiated?
- To what extent must they be used? Since Stage 3 extends through commercial batch manufacturing, what happens to Phase 3?
- Does it follow along or with Stage 3? Questions that exist include how one manages special situations to include viral inactivation and removal, impurity clearance, process consistency, process solution stability, endotoxin, bioburden, and other miscellaneous cell culture tests to include DNA and host cell protein.
These questions will be addressed within Stage 2 as presented here and include utilization of Process Validation and Phase 1, 2 and 3, where their Guidances blend and where they remain distinct. In particular, Stage 3.
Important: Please plan to bring a multidisciplinary group from your Company to gain the most from this very important seminar.
Why these FDA Guidance/EU Guidelines for Industry - Process Validation is so important to the pharmaceutical and biotechnology industry.
- What FDA segments are included and excluded within the "NEW" Process Validation.
- Where does the Process Validation commence.
- What are the Three Stages and Where Do They Apply within the NEW Process Validation.
- How Stage 1 integrates with Phase 1.
- The Validation approaches that are included within this Guidance document.
- The Statutory and Regulatory Requirements for Process Validation.
- An Introduction tPhase 1 Guidance for Industry and Its Application within the "NEW" Process Validation.
- The Phase 1 Investigational Drug Requirements -- What is and What is NOT Required.
- General Considerations for Process Validation - Stage 2 Process Qualification.
- Regulatory Strategies for Phase 2 and 3 and their Incorporation within Stages 1 and 2.
- General Considerations for Process Validation - Stage 3 Continued Process Verification.
- A Review of EU Annex 15 and its Comparison tFDA's Process Validation Guidance.
Who Will Benefit:
Those who will benefit from this seminar include
- Product Development
- Project Management
- Regulatory Compliance
- Quality Assurance
- Quality Control
- Manufacturing and Facilities professionals who are required to develop and participate in understanding issues surrounding Process Validation.
|Day One (8:30 AM – 5:00 PM)
||Day Two (8:30 AM – 4:30 PM)
Registration Process: 8:30 AM – 9:00 AM
Session Start Time: 9:00 AM
- Introduction, Goals and Objectives, Definitions. Process Validation - Its Importance within the Drug Industry
- Interaction of the Three Stages with Process Validation
- Validation Approaches, cGMPs in Clinical Supply Manufacture, Special Manufacturing Situations within Phase 1
- The Requirements of Phase 1 Investigational Drug Requirements
- Regulatory Strategies for Phase 2 and 3 and their Incorporation within Stages 1 and 2
- General Considerations for Process Validation – Stage 2 Process Qualifications
- Special Considerations for Process Validation – Stage 2
- General Considerations for Process Validation – Stage 3 Continued Process Verification
- A Review of EU Annex 15 and its Comparison to FDA’s Process Validation Guidance
- Concurrent Release of Process Performance Qualification (PPQ) Batches
- Analytical Methodology and Process Validation; Warning Letter examples
Meet Your Instructor
||Barry A. Friedman, Ph.D
Consultant in Biotechnology, Regulatory Compliance and Aseptic Processing Arena
Barry A. Friedman, PhD, is a Consultant in the Biotechnology, Regulatory Compliance and Aseptic Processing Arena. Dr. Friedman possesses over 30 years of industrial managerial experience in various aspects of biopharmaceuticals and medical devices to include regulatory compliance, expert witness testimony, GLP/GMP, quality control, auditing, sterility assurance, microbiological/analytical validations and fermentation technology.
Prior to becoming an independent consultant, Dr. Friedman was associated with Cambrex Bio Sciences, a contract manufacturer of GMP bulk biopharmaceuticals located in Baltimore, Maryland. As the Director of Quality Control, he managed a multi-shift Department of thirty one individuals involved in client management, the receipt and testing of raw materials, environmental monitoring and microbiology, analytical chemistry and QC compliance for the production of Phase 1, 2, 3 and commercial products manufactured from bacteria, yeast and mammalian cells. In this capacity, Dr Friedman enjoyed many client and regulatory interactions, both domestic and international.
Prior to 2000, Dr. Friedman was the Laboratory Director for Chesapeake Biological Laboratories, a contract Aseptic Fill n’ Finish manufacturer located in Baltimore, Maryland. In addition to the professional history listed above, other associations have included W.R. Grace, Sigma Chemical Co., Sherwood Medical, Becton Dickinson, American Cyanamid and Union Carbide.
Dr. Friedman received his B.S. degree in Microbiology from Ohio State University, his M.S. from Michigan State University in Microbial Genetics, and his PhD from Ohio State University in Microbiology.
Register by P.O. / Check
Yes, I want to attend "Process Validation Guidance Requirements (FDA and EU Annex 15: Qualifications and Validation)".
Click here to download P.O. form
If you are paying by check:
Checks should be payable to MetricStream Inc. (our parent company) and mailed to:
2479 East Bayshore Road
Palo Alto, CA 94303
Send your team for maximum benefit.
Get your team up to speed!
Significant tuition discounts are available for teams of two or more from the same company. You must register at the same time and provide a single payment to take advantage of the discount.
||Get 10% off
|3 to 6 Attendees
||Get 20% off
|7 to 10 Attendees
||Get 25% off
||Get 30% off
Call toll free on +1-888-717-2436 if you have any queries.
Register by Wire Transfer
If you wish to pay by wire transfer, please call us toll free on +1-888-717-2436
Terms & Conditions to Register for the Seminar/Conference/Event
Your registration for the seminar is subject to following terms and conditions. If you need any clarification before registering for this seminar please call us @ +1-888-717-2436 or email us @ firstname.lastname@example.org
Payment is required 2 days before the date of the conference. We accept American Express, Visa and MasterCard. Make checks payable to MetricStream Inc. (our parent company).
Cancellations and substitutions:
Written cancellations through fax or email (from the person who has registered for this conference) received at least 10 calendar days prior to the start date of the event will receive a refund — less a $200 administration fee. No cancellations will be accepted — nor refunds issued — within 10 calendar days before the start date of the event.
On request by email or fax (before the seminar) a credit for the amount paid minus administration fees ($200) will be transferred to any future ComplianceOnline event and a credit note will be issued.
Substitutions may be made at any time. No-shows will be charged the full amount.
We discourage onsite registrations, however if you wish to register onsite, payment to happen through credit card immediately or check to be submitted onsite. Conference material will be given on the spot if it is available after distributing to other attendees. In case it is not available, we will send the material after the conference is over.
In the event ComplianceOnline cancels the seminar, ComplianceOnline is not responsible for any airfare, hotel, other costs or losses incurred by registrants. Some topics and speakers may be subject to change without notice.
Attendance confirmation and documents to carry to the seminar venue:
After we receive the payment from the registered attendee, an electronic event pass will be sent to the email address associated with the registrant 5 working days before the seminar date. Please bring the pass to the venue of the event.
Conference photograph / video:
By registering and attending ComplianceOnline conference, you agree to have your photographs or videos taken at the conference venue and you do not have any objections to ComplianceOnline using these photos and videos for marketing, archiving or any other conference related activities. You agree to release ComplianceOnline from any kind of claims arising out of copyright or privacy violations.
If you wish to partner with us for this event
contact us: email@example.com
call us: +1-888-717-2436.
Media Partner Benefits
- Logo and company data on the event website.
- Logo on the conference material distributed during the conference.
- Media partner’s brochure distributed along with conference material.
- Logo on all the mailings before and after the event.
- 10% discount to media partner's subscribers.
Media Partner To Do
- Banner (min 728x90 or 468x60) on the media partner website.
- Insertion of the event in the event calendar, both printed and/or online.
- Announcement article of the conference on the magazine and/or website.
- Dedicated email blast to media partner’s subscribers.
- Article on the magazine and/or website after the conference.
If you wish to sponsor this event
contact Cruise Webster: firstname.lastname@example.org
call us: (207) 576-4173
The Museu Picasso, located in Barcelona, houses one of the most extensive collections of artworks by the 20th-century Spanish artist Pablo Picasso. With 4,251 works exhibited by the painter, the museum has one of the most complete permanent collections of works. The museum is housed in five adjoining medieval palaces in Barcelona's La Ribera and is located on Montcada Street in the (Bank District) of Barcelona. It opened to the public on 9 March 1963, becoming the first museum dedicated to Picasso's work and the only one created during the artist's life. It has since been declared a (museum of national interest) by the Government of Catalonia.
Camp Nou, often referred to as the "Nou Camp", is a football stadium in Barcelona. It has been the home of FC Barcelona since its completion in 1957. With a seating capacity of 99,354, it is the largest stadium in Spain by capacity. It is also the largest stadium in Europe and the third largest association football stadium in the world in terms of capacity. It has hosted numerous international matches at a senior level, including a 1982 FIFA World Cup semi-final match, two UEFA Champions League finals and the football competition at the 1992 Summer Olympics.
The Park Guell is a public park system composed of gardens and architectonic elements located on Carmel Hill, in Barcelona, Catalonia. Carmel Hill belongs to the mountain range of Collserola — the Parc del Carmel is located on the northern face. Park Güell is located in La Salut, a neighborhood in the Gràcia district of Barcelona. The park was built between 1900 and 1914 and was officially opened as a public park in 1926. The park was originally part of a commercially unsuccessful housing site, the idea of Count Eusebi Guell, after whom the park was named. It was inspired by the English garden city movement; hence the original English name Park. In 1984, UNESCO declared the park a World Heritage Site under “Works of Antoni Gaudí.”
La Rambla is a street in central Barcelona, popular with tourists and locals alike. A tree-lined pedestrian mall, it stretches for 1.2 kilometres connecting Plaça de Catalunya in the centre with the Christopher Columbus Monument at Port Vell. La Rambla forms the boundary between the quarters of Barri Gòtic, to the east, and El Raval, to the west.
The Gothic Quarter is the centre of the old city of Barcelona. It stretches from La Rambla to Via Laietana, and from the Mediterranean seafront to Ronda de Sant Pere. Despite several changes undergone in the 19th and early 20th century, many of the buildings date from Medieval times, some from as far back as the Roman settlement of Barcelona. Remains of the squared Roman Wall can be seen around Tapineria and Sots-Tinent Navarro to the north, Avinguda de la Catedral and Plaça Nova to the west and Carrer de la Palla to the south. El Call, the medieval Jewish quarter, is located within this area too. The Barri Gòtic retains a labyrinthine street plan, with many small streets opening out into squares. Most of the quarter is closed to regular traffic although open to service vehicles and taxis.
Casa Mila, popularly known as La Pedrera, is a modernist building in Barcelona. It was the last civil work designed by Catalan architect Antoni Gaudí, built between the years 1906 and 1912. At the time, it was controversial because of the undulating stone facade and twisting wrought iron balconies and windows designed by Josep Maria Jujol. Architecturally it is considered structurally innovative, with a self-supporting stone front and columns, and floors free of load bearing walls. Also innovative is the underground garage. In 1984 it was declared a World Heritage Site by UNESCO. Currently, it is the headquarters of the Catalunya-La Pedrera Foundation, which manages the exhibitions, activities and public visits at Casa Mila.